Thyroid Cancer
Papillary thyroid carcinoma · Follicular thyroid cancer · Medullary thyroid cancer · Anaplastic thyroid cancer | ICD-10 C73
Thyroid cancer is a malignancy of the thyroid gland in the front of the neck, most often papillary carcinoma. Incidence has risen sharply in South Korea, the United States and parts of Europe and Asia, largely because ultrasound detects small, indolent tumours, while mortality has remained low. Many small low-risk cancers can be monitored rather than operated on immediately.
A thyroid nodule is common and the great majority are benign. The worldwide rise in thyroid cancer incidence over recent decades reflects widespread ultrasound use and overdiagnosis more than a true increase in aggressive disease — death rates have stayed low and flat. Recognising this is important for international patients: a scan finding does not automatically mean an operation is urgent.
When treatment is needed, the main decision is between active surveillance, hemithyroidectomy (lobectomy) and total thyroidectomy, with or without radioactive iodine and neck dissection. Medullary and anaplastic cancers are rare but require different pathways, including RET genetic testing for medullary disease and urgent multimodality care for anaplastic disease.
Where in the world is thyroid cancer common?
about 820,000 new thyroid cancer cases worldwide (GLOBOCAN 2022 estimate) were estimated worldwide in 2022 (ASR 9.1 per 100,000 overall (women 13.6, men 4.6); mortality ASR only 0.4).
Asia accounted for 72.7% of global thyroid cancer cases in 2022 (596,600 cases) and 61.3% of deaths, with incidence strongly correlated with human development index and diagnostic intensity.
| Region / country | What the data show |
|---|---|
| South Korea | The highest age-standardised incidence in Asia — 7.6/100,000 in men and 39.5/100,000 in women — driven largely by intensive ultrasound screening and overdiagnosis of small papillary cancers. |
| China | The largest absolute burden in Asia (about 466,000 new cases in 2022 across both sexes in one GLOBOCAN-based analysis), with wide regional variation in diagnostic intensity. |
| United States & Canada | High and rising incidence with stable mortality; active surveillance of low-risk papillary microcarcinoma is now an accepted option in guidelines. |
| Italy, France & Southern Europe | Among the highest incidence rates in Europe, again largely reflecting ultrasound and opportunistic screening. |
| United Arab Emirates & Gulf states | A 2026 Asian analysis reported the highest thyroid cancer mortality ASR in the region (0.9 in men, 13.9 in women per 100,000), illustrating that incidence and mortality rankings can differ. |
| Australia & New Zealand | High detection rates in high-income health systems, with excellent survival for differentiated disease. |
What are the risk factors?
- Ionising radiation exposure to the head and neck, especially in childhood
- Family history of thyroid cancer and inherited syndromes (MEN2/RET, Cowden, familial adenomatous polyposis)
- Female sex — incidence is roughly three times higher in women
- Iodine deficiency (follicular cancer) or, in some settings, high iodine intake
- Hashimoto thyroiditis (associated with papillary carcinoma and thyroid lymphoma)
- Increasing age and high ultrasound/screening exposure (detection rather than biological risk)
What are the signs and symptoms?
- A painless, firm nodule in the front of the neck that moves on swallowing
- Hoarseness or voice weakness from recurrent laryngeal nerve involvement
- Difficulty swallowing or breathing, or a sensation of pressure when lying flat
- Enlarged cervical lymph nodes, sometimes the only sign of papillary cancer
- Rapidly enlarging neck mass and neck pain (warning signs for anaplastic or lymphoma)
- Most small thyroid cancers cause no symptoms at all and are found incidentally on ultrasound
Two-to-three-week rule: any head or neck symptom that persists beyond two to three weeks should be examined by an ENT specialist with an endoscope — pain is usually a late feature, not an early one.
How is it diagnosed and staged?
- Thyroid function tests (TSH) and high-resolution neck ultrasound with a structured TI-RADS report
- Ultrasound-guided fine-needle aspiration (FNA) reported with the Bethesda classification
- Calcitonin and CEA when medullary carcinoma is suspected; RET genetic testing if confirmed
- Vocal cord assessment (laryngoscopy) before thyroid surgery, especially with hoarseness or prior neck surgery
- Contrast CT/MRI for locally advanced disease, substernal extension or nodal mapping
- Molecular testing of indeterminate nodules in selected cases; review by an experienced thyroid pathologist
AJCC 8th edition TNM staging for differentiated thyroid cancer incorporates age at diagnosis (using 55 years as the cut-off in the current system), tumour size and gross extrathyroidal extension, nodal metastases and distant metastases. A 45-year-old with a small node-positive papillary cancer can be stage I, which is a frequent source of confusion for patients.
What are the treatment options?
- Active surveillance with serial ultrasound for selected low-risk papillary microcarcinomas
- Thyroid lobectomy for small, unifocal, intrathyroidal tumours without nodal disease
- Total thyroidectomy when indicated by size, multifocality, extrathyroidal extension, nodal disease or patient preference
- Therapeutic neck dissection for clinically involved nodes; radioactive iodine (I-131) for selected intermediate/high-risk differentiated cancers
- TSH suppression with levothyroxine tailored to risk; lifelong hormone replacement after total thyroidectomy
- Targeted therapy (e.g. multikinase inhibitors, BRAF/MEK or RET inhibitors) for progressive radioactive-iodine-refractory disease; urgent multimodality therapy for anaplastic carcinoma
Decisions should be made by a multidisciplinary tumour board, with speech, swallowing and appearance considered alongside cancer control. See how treatment changes with stage →
What is the prognosis?
Differentiated papillary and follicular thyroid cancer generally has excellent outcomes; five-year survival for localised papillary cancer is commonly reported above 98%, and even regional disease has high survival. Medullary carcinoma has an intermediate outlook, while anaplastic carcinoma is aggressive with short survival. Age, size, extrathyroidal extension, nodal burden, distant metastasis and histology drive individual risk.
Survival figures are population averages from registry data, not predictions for an individual. See the follow-up schedule →
Can it be prevented?
- Avoid unnecessary ionising radiation to the head and neck in children; use thyroid shielding when medically appropriate
- Maintain adequate dietary iodine; neither deficiency nor excessive supplementation is protective against cancer
- Genetic counselling and RET testing for families with MEN2 or medullary thyroid cancer
- There is no recommended general-population ultrasound screening — it increases overdiagnosis without lowering mortality
- Evaluate a new or growing neck nodule with ultrasound and FNA rather than repeated empirical medication
Prevention by region: HPV vaccine, areca nut, tobacco and UV →
Treatment in China for international patients
Chinese tertiary centres perform very high volumes of thyroid surgery with intraoperative recurrent laryngeal nerve monitoring and parathyroid preservation. For international patients, the most valuable service is often a careful re-assessment of whether surgery is needed at all, since many incidental small nodules qualify for active surveillance.
- Bring the original ultrasound images and report, FNA/Bethesda result, thyroid function tests and any molecular test results.
- Ask for a written indication: surveillance, lobectomy or total thyroidectomy, with the reasons and the expected need for lifelong levothyroxine.
- Ask about recurrent laryngeal nerve monitoring, postoperative calcium/parathyroid management and how vocal cord function is checked.
- If radioactive iodine is proposed, confirm isotope availability, isolation requirements and the timing of whole-body scanning before you travel home.
Cost guidance: As an illustrative planning range, thyroid lobectomy is often budgeted at ¥25,000–¥55,000 (about US$3,500–7,700), total thyroidectomy with neck dissection ¥45,000–¥100,000, and radioactive iodine ¥15,000–¥40,000 per treatment. These are budgeting figures, not a quotation, and a surveillance pathway costs far less than surgery.
Compare the pathway, records checklist and aftercare planning on the international patients page.
All 14 questions about thyroid cancer
Each question has its own page with a direct answer, practical detail and the sources behind it — the same structure used on Dr. Liu’s Chinese knowledge base.
Understanding the disease
3 questionsWhat the tumour is, where in the world it is common, who gets it and why.
Symptoms & diagnosis
3 questionsThe warning signs, the biopsy, the scans and what staging actually means.
Treatment
2 questionsSurgery, radiotherapy, chemotherapy, immunotherapy and organ-preserving options.
Side effects & recovery
1 questionWhat treatment feels like, how side effects are managed, and rehabilitation.
Prognosis & follow-up
2 questionsSurvival figures in context, recurrence risk and the follow-up schedule.
Prevention & risk
2 questionsHPV vaccination, tobacco and areca nut, UV protection and occupational exposure.
Treatment in China
1 questionWhat international patients should prepare, timelines, costs and aftercare.
Frequently asked questions
What is thyroid cancer?
Thyroid cancer is a malignancy of the thyroid gland in the front of the neck, most often papillary carcinoma. Incidence has risen sharply in South Korea, the United States and parts of Europe and Asia, largely because ultrasound detects small, indolent tumours, while mortality has remained low. Many small low-risk cancers can be monitored rather than operated on immediately.
Where in the world is thyroid cancer most common?
Thyroid Cancer is not evenly distributed: the highest-burden regions are South Korea, China and United States & Canada. In 2022 there were about 820,000 new thyroid cancer cases worldwide (GLOBOCAN 2022 estimate) worldwide (ASR 9.1 per 100,000 overall (women 13.6, men 4.6); mortality ASR only 0.4), with marked country-to-country variation driven by local exposures such as tobacco, areca nut, oncogenic viruses, ultraviolet radiation and occupational carcinogens.
What are the risk factors for thyroid cancer?
The main recognised risk factors for thyroid cancer are ionising radiation exposure to the head and neck, especially in childhood, family history of thyroid cancer and inherited syndromes (MEN2/RET, Cowden, familial adenomatous polyposis) and female sex — incidence is roughly three times higher in women. Risks differ by region: South Korea has a distinctive exposure pattern, so a patient's country of residence is part of the risk assessment. Having a risk factor does not mean a person will develop cancer.
What are the early signs of thyroid cancer?
The common early signs are a painless, firm nodule in the front of the neck that moves on swallowing, hoarseness or voice weakness from recurrent laryngeal nerve involvement, difficulty swallowing or breathing, or a sensation of pressure when lying flat and enlarged cervical lymph nodes, sometimes the only sign of papillary cancer. Head and neck tumours often cause mild, one-sided symptoms that mimic a cold, a dental problem or a sore throat. Any symptom in the head or neck that persists for more than two to three weeks needs an ENT examination rather than repeated antibiotics.
How is thyroid cancer diagnosed and staged?
Diagnosis requires a tissue biopsy read by a head and neck pathologist, supported by endoscopic examination and contrast CT or MRI of the neck; PET-CT is added when nodal or distant spread is suspected. Staging uses the AJCC TNM system and guides whether surgery, radiotherapy, chemoradiotherapy or systemic therapy is the primary treatment.
What are the treatment options for thyroid cancer?
Treatment is stage- and site-specific, and usually combines active surveillance with serial ultrasound for selected low-risk papillary microcarcinomas, thyroid lobectomy for small, unifocal, intrathyroidal tumours without nodal disease and total thyroidectomy when indicated by size, multifocality, extrathyroidal extension, nodal disease or patient preference. Early-stage disease is generally treated with one modality (surgery or radiotherapy), while locally advanced disease needs combined modality treatment planned by a multidisciplinary team.
What is the prognosis for thyroid cancer?
Differentiated papillary and follicular thyroid cancer generally has excellent outcomes; five-year survival for localised papillary cancer is commonly reported above 98%, and even regional disease has high survival. Medullary carcinoma has an intermediate outlook, while anaplastic carcinoma is aggressive with short survival. Age, size, extrathyroidal extension, nodal burden, distant metastasis and histology drive individual risk.
Can thyroid cancer be prevented?
Many cases are preventable. The most useful steps for thyroid cancer are avoid unnecessary ionising radiation to the head and neck in children; use thyroid shielding when medically appropriate, maintain adequate dietary iodine; neither deficiency nor excessive supplementation is protective against cancer and genetic counselling and RET testing for families with MEN2 or medullary thyroid cancer. Prevention works best before exposure begins, but stopping tobacco, areca nut and heavy alcohol use still lowers risk after many years of use.
Why is thyroid cancer incidence rising so fast in South Korea and other wealthy countries?
Most of the rise is overdiagnosis: widespread neck ultrasound detects tiny papillary cancers that would never have caused symptoms or death. South Korea has the highest reported incidence in Asia (39.5/100,000 in women), yet thyroid cancer mortality remains low and stable. In other words, more cancers are being found, not necessarily more dangerous ones.
Can a small papillary thyroid cancer be watched instead of removed?
Yes, for selected low-risk tumours — typically a small intrathyroidal papillary microcarcinoma without nodal metastases, extrathyroidal extension, aggressive cytology or unfavourable location. Active surveillance means periodic high-resolution ultrasound, with surgery if the nodule grows, nodes appear or the patient prefers treatment.
What does a Bethesda result on my thyroid FNA report mean?
The Bethesda System classifies thyroid fine-needle aspiration cytology into six categories from I (non-diagnostic) to VI (malignant), each with an estimated risk of malignancy and a recommended action — repeat FNA, molecular testing, lobectomy or total thyroidectomy. It is a risk-stratification tool, not a final diagnosis in the indeterminate categories.
What are the main risks of thyroid surgery?
The specific risks are injury to the recurrent laryngeal nerve (hoarseness or, rarely, bilateral vocal cord paralysis), hypoparathyroidism with low calcium (usually temporary, occasionally permanent), bleeding, and the need for lifelong levothyroxine after total thyroidectomy. Intraoperative nerve monitoring and meticulous parathyroid preservation reduce but do not eliminate these risks.
What follow-up is needed after thyroid cancer treatment?
Follow-up usually combines neck ultrasound, serum thyroglobulin (with anti-thyroglobulin antibodies) for differentiated cancer after total thyroidectomy, TSH and free T4 to guide levothyroxine, and calcitonin/CEA for medullary cancer. Frequency is highest in the first one to two years and decreases as the risk of recurrence falls.
How much does thyroid cancer treatment in China cost for international patients?
Illustrative planning ranges are ¥25,000–¥55,000 (about US$3,500–7,700) for lobectomy, ¥45,000–¥100,000 for total thyroidectomy with neck dissection, and ¥15,000–¥40,000 per radioactive iodine treatment. Active surveillance with ultrasound costs far less. These are budgeting figures, not a quotation.
Sources for this topic
Ask about thyroid cancer treatment in China
Send your pathology report, biomarker results and imaging for a written preliminary opinion before making travel plans.
What to send Contact the clinicMedical disclaimer: This knowledge base is general information for people researching head and neck tumours, not a diagnosis or treatment plan. It does not replace an examination by a qualified physician. Survival figures are population averages, not predictions for an individual. Treatment and cost estimates for China are illustrative only and must be confirmed in writing after your records have been reviewed. If you have a symptom lasting more than two to three weeks, see a doctor promptly.